{"data":{"type":"company_profile","id":71748,"entity_id":"wefunder:company:71748","attributes":{"canonical_url":"https://wefunder.com/innamed","generated_at":"2026-06-16T10:21:58Z","updated_at":"2026-06-16T05:02:29Z","entity_ids":{"company":"wefunder:company:71748","slug":"wefunder:company_slug:innamed"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-16T10:21:58Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-16T05:02:29Z","as_of":"2026-06-16T10:21:58Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-16T05:02:29Z","as_of":"2026-06-16T10:21:58Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-05-27T20:41:43Z","as_of":"2026-06-16T10:21:58Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-05-27T20:41:43Z","as_of":"2026-06-16T10:21:58Z","confidence":"medium"}}},"company":{"id":71748,"entity_id":"wefunder:company:71748","slug":"innamed","name":"InnaMed (YC W17)","tagline":"Using at-home blood testing technology to enable personalized medicine","elevator_pitch":"InnaMed makes monitoring and analyzing blood test data fast and seamless. Blood monitoring is a key component of getting the right patients on the right therapies at the right doses, but it's far too tedious today. InnaMed’s patented, flagship product, the HomeLab® system, enables push button blood testing in the home.","story":"Creating the gateway to personalized healthcare. Interfacing with the healthcare system is notoriously challenging. Scheduling appointments, determining insurance coverage, traveling, waiting, testing, scanning, picking up prescriptions, etc.…the list of manual tasks goes on and on.\u0026nbsp;At InnaMed, we have reimagined a major part of this journey: we make monitoring and analyzing blood test data fast and seamless, and we’re also creating a one-stop platform through which you can access and experience digital health services.Measure, analyze, enhance: from the comfort \u0026amp; privacy of home.Monitoring and analyzing blood test data is crucial to several healthcare decisions.\u0026nbsp;Clinical trials rely on blood monitoring to determine safety, efficacy, and optimal dosing of new therapies. Each patient that is non-adherent to dosing and monitoring adds $25,000+ in clinical trial costs.In medical practice, patients with complex conditions such as heart failure or organ transplant are usually on several drugs at once. Many therapeutics have a narrow therapeutic range and side effects (kidney or liver toxicity). If not taken at the right doses or frequencies, they can have adverse health consequences.\u0026nbsp;Blood monitoring is a key component of getting the right patients on the right therapies, at the right doses.The impact of therapeutic optimization is undeniable in clinical outcomes. For example, transplant patients who maintain immunosuppressant levels within range are nearly 70% less likely to experience rejection. Similarly, heart failure patients who take guideline medication have over 30% reduced mortality. The precise dosing of medications is important and often requires careful blood monitoring.\u0026nbsp;While discovering new therapies is important, utilizing those therapies properly is just as important to safely achieving their maximum potential. That is where InnaMed can make a difference. We let you measure + analyze + enhance – all from the comfort and\u0026nbsp;privacy of home.\u0026nbsp;A connected hub for your health needs. InnaMed’s flagship product, the HomeLab® system, enables push button blood testing in the home. There are three components to the system: 1) a disposable, one-time-use blood collector for virtually painless self-sampling, 2) a disposable, one-time-use cartridge for sample analysis and 3) a counter-top IoT device which reads results, conducts symptom surveys, and handles communication\u0026nbsp;with cloud services.\u0026nbsp;A single HomeLab cartridge can perform up to 24 unique tests. Our first cartridge, HomeLab RMX, tests for a panel of metabolic markers commonly used in clinical decision making. This cartridge is useful in monitoring patients in clinical trials or patients with chronic illnesses who are undergoing therapeutic changes.\u0026nbsp;InnaMed has several additional cartridges in its development pipeline, targeting conditions such as organ transplant, rare diseases, and autoimmune diseases. Several pipeline cartridges have pharma collaborators funding development and pre-ordering units.Enabled by biosensor technology.HomeLab cartridges function using proprietary fluidics and electrochemistry. Our technology can measure proteins and peptides, small molecule drugs, hormones, antibodies, and standard clinical chemistries. Tests can be performed in as quickly as 10 minutes, with detection of femtomolar (10^-15) concentrations.\u0026nbsp;InnaMed has a growing portfolio of 9 patents and 5 publications on its technology and has performed studies with patient samples demonstrating strong correlation to clinical labs. This technology can be expanded from blood to urine and even saliva samples in the future.Precision medicine, powered by the cloud.\u0026nbsp;In addition to blood testing, InnaMed’s HomeLab has a suite of connectivity features. Bluetooth, Wi-Fi, cellular and NFC ensure reliable and easy connectivity. Blood test data along with survey and vitals data is packaged into a comprehensive e-report. These e-reports can be synced to EMR or LIMS systems, integrating into existing clinical and research workflows, or viewed on InnaMed’s custom HomeLab web application.\u0026nbsp;Data consolidation enables analysis on patient, provider, organization, and disease scales with sufficient resolution to understand time variance. The deidentified data lake generated by HomeLab devices can become a monetizable asset its\u0026nbsp;own.\u0026nbsp;Downstream of data analysis is integration with the healthcare experience. InnaMed plans to integrate available digital health services onto the HomeLab platform, creating a truly one-stop experience.Unique positioning to revolutionize a legacy industry. The personalized medicine platform being built by InnaMed holds tremendous value for not just patients and providers but also pharmaceutical companies and contract research organizations (CROs). InnaMed’s initial business model involves selling the HomeLab and HomeLab RMX cartridges to pharmaceutical companies and CROs on a subscription basis to enhance and digitize clinical trials. The virtual clinical trial market is expected to reach $14B in 2027 and is growing at an annual rate of 12.6%. InnaMed is also collaborating with pharmaceutical companies to develop tailor-made cartridges. In many cases, such research collaborations do not require FDA clearance, enabling pre-regulatory revenue.Simultaneously, InnaMed is pursuing regulatory clearance for the HomeLab and HomeLab RMX cartridge for patient use outside of the clinical trial setting, aiming to aid providers in implementing and optimizing medical guideline recommended therapy in the real world. The company has had multiple presubmission meetings and is working closely with FDA for both clinical and research use cases.InnaMed is initially targeted towards specific clinical applications totaling $5B+ in market potential.\u0026nbsp;The at-home diagnostics and personalized medicine industry is poised to accelerate, providing InnaMed with significant growth opportunity.\u0026nbsp;The company has several multi-year pharma R\u0026amp;D collaborations and generated over $1.4M in revenue in 2020. With 7 full-time employees, expert executive guidance and a large team of contractors and consultants supporting manufacturing, regulatory and commercial efforts, InnaMed is ready to become a leading telemedicine technology company.Become an owner of InnaMed – positive social impact with strong potential for\u0026nbsp;financial upside\u0026nbsp;Invest now to make healthcare easier for the millions of patients who are unhappy with the status quo. With your investment, we will finish pilot manufacturing of HomeLab, conduct FDA 510(k) clinical studies and achieve regulatory clearance within a year’s time.","location":"Philadelphia, PA","website":"https://www.innamed.com/","total_amount_raised":1217306,"total_investors":1390,"is_funded":true,"is_active":true,"quality_score":5,"related_urls":["https://wefunder.com/innamed","https://www.innamed.com/"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/71748/xxl_cropped_04.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/71748/large_cropped_Icon_Green.jpg","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/71748/standard_cropped_04.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/71748/standard_cropped_04.jpg","profile_video_url":"https://wefunder.wistia.com/medias/6chul38r9n"},"links":{"company_url":"https://www.innamed.com/"},"highlights":[{"id":62735,"name":"y_combinator","url":"ycombinator","presentable_name":"Y Combinator","description":"Raised from Y Combinator","image_url":"https://uploads.wefunder.com/2021/profile-highlights-yc.svg"}],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"Raised $2M+, backed by Y Combinator and leading Silicon Valley investors"},{"index":2,"claim_id":"claim-fact-2","value":"$1.4M+ in revenue in 2020 (6x YoY) from ongoing, multi-year pharmaceutical R\u0026amp;D collaborations"},{"index":3,"claim_id":"claim-fact-3","value":"Received grants from NASA and US Dept. of Health \u0026amp; Human Services for innovative HomeLab® technology"},{"index":4,"claim_id":"claim-fact-4","value":"9 patent applications and 5 peer-reviewed publications on technology"},{"index":5,"claim_id":"claim-fact-5","value":"Initially targeted towards specific clinical applications totaling $5B+ in market potential"},{"index":6,"claim_id":"claim-fact-6","value":"Led by innovators from UPenn and experienced execs from UCSF, Duke, $ASND, $ABT, and $CDNA"}],"team":[{"id":1209357,"entity_id":"wefunder:company_role:1209357","user_entity_id":"wefunder:user:1203622","role":"founder","name":"Eshwar Inapuri","title":"CEO","bio":"Y Combinator-backed founder and bioengineer. Previously conducted R\u0026amp;D at UPenn for 4+ years combining microfluidics, optics and cloud computing to develop proteomics. Work published in PNAS and exclusively licensed to another venture-backed startup.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/1209357/square_cropped_pic.jpg?1613421616","profile_url":"https://wefunder.com/eshwar.inapuri","linkedin_url":"https://www.linkedin.com/in/eshwar-inapuri/","related_urls":["https://wefunder.com/eshwar.inapuri"]},{"id":1428383,"entity_id":"wefunder:company_role:1428383","user_entity_id":"wefunder:user:1356816","role":"founder","name":"Anup Singh","title":"CSO","bio":"Y Combinator-backed founder and biophysicist. Previously conducted R\u0026amp;D for 5+ years at UCLA and UPenn on early detection of cancers and traumatic brain injury. Invited conference speaker topics ranging from precision medicine to space health.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/1428383/square_cropped_Y-Combinator-713_2-01_3s.jpg?1614010137","profile_url":"https://wefunder.com/anup.singh.2","linkedin_url":"https://www.linkedin.com/in/anup-singh-229678b3/","related_urls":["https://wefunder.com/anup.singh.2"]},{"id":1466140,"entity_id":"wefunder:company_role:1466140","role":"employee","name":"Tom Larson","title":"Commercial Development Lead","bio":"Executive with 25+ years of experience in the biopharma and diagnostics industries. Most recently served as Chief Commercial Officer of Ascendis Pharma. Led launches of some of the most successful drugs including Humira and Pradaxa.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/1466140/square_cropped_1516565558914.jpg?1613427486","linkedin_url":"https://www.linkedin.com/in/tom-larson-72566015/","related_urls":[]},{"id":1466143,"entity_id":"wefunder:company_role:1466143","role":"employee","name":"Kenneth Fang","title":"Clinical Development Lead","bio":"Executive with 20+ years of experience in diagnostics. Most recently Chief Medical Officer (CMO) of Diadexus. Prior to that, served as CMO at Integrated Diagnostics and Senior Director at CareDx. Prior to industry, was an Assistant Professor at UCSF.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/1466143/square_cropped_1517673866336.jpg?1613425783","linkedin_url":"https://www.linkedin.com/in/kennethfang/","related_urls":[]},{"id":1466145,"entity_id":"wefunder:company_role:1466145","role":"employee","name":"Chris Easley","title":"Scientific Advisor","bio":"Professor at Auburn University with 20+ years of experience in analytical chemistry. Developed and patented foundational technologies exclusively licensed by InnaMed. Featured in prestigious journals (Nature, PNAS, JACS) and backed by NIH and NSF.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/1466145/square_cropped_1531860569230.jpg?1613422746","linkedin_url":"https://www.linkedin.com/in/christopher-easley-78b824a2/","related_urls":[]}],"featured_investors":[{"id":5215,"entity_id":"wefunder:company_investor_profile:5215","investor_profile_id":897422,"investor_profile_entity_id":"wefunder:investor_profile:897422","subject_entity_id":"wefunder:user:1364400","name":"Daniel Robert Bensimhon","avatar_url":"https://uploads.wefunder.com/2021/user_default_icon_circle.png","profile_url":"https://wefunder.com/danielrobertbensimhon","investment_total":50000,"investment_info":"Invested $25,000 this round \u0026 $25,000 previously","is_lead_investor":true,"related_urls":["https://wefunder.com/danielrobertbensimhon"]}],"investor_memos":[],"tab_counts":{"posts":0,"ask_questions":73,"featured_investors":1,"faq_entries":5},"active_fundraises":[{"id":38499,"entity_id":"wefunder:fundraise:38499","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":100000.0,"funding_started_at":"2021-02-19T01:15:12Z","funding_closed_at":"2021-05-29T05:03:49Z","auto_close_at":"2021-05-29T03:59:59Z"}],"latest_fundraise":{"id":38499,"entity_id":"wefunder:fundraise:38499","state":"successful","offering_type":"4(a)(6)","structure":"safe","testing_the_waters":false,"can_invest_now":false,"funding_started_at":"2021-02-19T01:15:12Z","funding_closed_at":"2021-05-29T05:03:49Z","terms":{"eb":null,"nb":"$25M","txt":"valuation cap"}},"recent_posts":[],"q_and_a":[{"id":133887,"entity_id":"wefunder:comment:133887","question":"I really love what you guys are building. Are there any future plans to give direct access to health conscious consumers? I would purchase one simply because it makes no sense to have to schedule an appointment with a doctor just so he/she can then order lab tests. I'd like to just do it at home, and share my results with a tele-medicine provider.","author_name":"D. William Zero","votes":9,"created_at":"2021-03-07T16:03:11Z","canonical_url":"https://wefunder.com/innamed#question-133887","answers":[{"id":134043,"entity_id":"wefunder:comment:134043","answer":"Potentially! It's an option we would consider in the future after our initial business applications.","author_name":"Eshwar Inapuri","votes":0,"created_at":"2021-03-09T02:15:53Z"}]},{"id":135618,"entity_id":"wefunder:comment:135618","question":"Hello, I had a few questions. 1) During your last crowdfunding on Republic, you expected that your product would have received FDA clearance by Q1 2021. Why has this not happened and what is the new timeline for clearance? 2) During your last crowdfunding, you indicated that you had eight letters of intent from leading hospitals interested in purchasing your product post-FDA clearance. How many LOIs from hospital systems do you have now? 3) Previously two cartridges were discussed for TeleLab--Telekidney and Teleheart--but now I only see a reference to HomeLab and no mention of either of these cartridges but to one called RMX which will test for renal function. Is it correct to say that this is the successor of the Telekidney, while the Teleheart cartridge has been put on the back-burner? 4) It appears that since your last crowdfunding, Alan Jernigan is no longer part of your team. Given his extensive experience in developing over 35 diagnostic solutions, why is this? Many thanks.","author_name":"Alexander L","votes":7,"created_at":"2021-03-17T23:32:13Z","canonical_url":"https://wefunder.com/innamed#question-135618","answers":[{"id":135636,"entity_id":"wefunder:comment:135636","answer":"1) We are now aiming for FDA clearance in early 2022, provided we raise sufficient capital. Our timeline was delayed due to extension of the design for manufacturing process (which we are now wrapping up). 2) We have pivoted from focusing on the hospital market to focusing on the pharmaceutical market (specifically virtual clinical trials). We have closed 4 pharmaceutical deals and generated $1.4m in revenue last year (6x YoY growth). 3) You are correct, the RMX cartridge is a more comprehensive successor to the Telekidney cartridge. The Teleheart cartridge is on the back-burner because it is not a critical product for the virtual clinical trial market. 4) Alan was serving as an advisor to the company while we were evaluating his suitability for the CEO role. After our pivot from the hospital market to the pharmaceutical market, we decided to mutually part ways with him and have since found a more experienced pharmaceutical industry advisor in Tom Larson to guide our commercial strategy (Tom got his career start in diagnostics before shifting over to the pharmaceutical industry - he's the perfect person to communicate our value to potential pharma clients).","author_name":"Eshwar Inapuri","votes":1,"created_at":"2021-03-18T00:59:02Z"}]},{"id":133289,"entity_id":"wefunder:comment:133289","question":"Hello, congratulations on your success so far. Can you provide a time-frame (approximately) when you are planning to convert to equity this SAFE and the convertible from the Republic round? What exit strategy you are vision? From a short research made to the non direct competitors you mentioned below, it seems your industry is capital-intensive and requires millions of funding (outside the spectrum of crowdfunding) for substantial progress. How you are planning to catch up with these competitors? Do you have plans of approaching VC or high net income investors further? What is your time estimation for FDA approval? In case you don't manage to get FDA approval, what is your back-up plan?","author_name":"Anna Varvara Makra","votes":4,"created_at":"2021-03-03T02:14:29Z","canonical_url":"https://wefunder.com/innamed#question-133289","answers":[{"id":133334,"entity_id":"wefunder:comment:133334","answer":"Hi Anna - happy to provide clarity. The SAFE from this round will be converted to equity upon a subsequent priced round financing. We are aiming to raise an institutional (VC-led) Series A later this year. When we do so, this event would trigger conversion of your SAFE to equity. As you stated, we will need additional capital to commercialize and an institutional Series A will provide that capital. From there, we can focus on growth (Series B followed by IPO) or exit (acquisition) opportunities and will select a direction based on our analysis of available options. We are aiming for FDA clearance in the first half of 2022 and we are confident that clearance is achievable provided we raise capital.","author_name":"Eshwar Inapuri","votes":4,"created_at":"2021-03-03T15:11:21Z"}]},{"id":142462,"entity_id":"wefunder:comment:142462","question":"congrats on breaking the 900k level!! Can't wait to see how this company grows.","author_name":"James Funaro","votes":3,"created_at":"2021-04-16T13:16:24Z","canonical_url":"https://wefunder.com/innamed#question-142462","answers":[{"id":142469,"entity_id":"wefunder:comment:142469","answer":"Thanks James! Appreciate the support.","author_name":"Anup Singh","votes":0,"created_at":"2021-04-16T14:41:10Z"}]},{"id":134012,"entity_id":"wefunder:comment:134012","question":"I like the product you guys are working on as I am currently working with my team on a digital health product. I am thinking of investing but I find the valuation of $25M steep given where you are. I expected $15M to max $20M. My questions are: 1. What makes Innamed's product special compared to other in-home lab testing start-ups/kits? 2. Do you have a full list of clinical markers the Innamed blood testing devices are capable of measuring? 3. How valuable is the result from the Innamed blood sample testing devices than buying any of the common urine test kits?\"","author_name":"Julien King","votes":3,"created_at":"2021-03-08T20:11:23Z","canonical_url":"https://wefunder.com/innamed#question-134012","answers":[{"id":134041,"entity_id":"wefunder:comment:134041","answer":"1. The range of analytes we can test for (proteins, antibodies, small molecules, clinical chemistries) is greater than those of other in-home lab testing startups/kits. Our product is intended for quantitative, comprehensive clinical monitoring as opposed to other products in development that are focused on infectious disease testing. 2. Our first cartridge will test for the basic metabolic panel (plus lactate and hematocrit) with other confidential proteomic tests available for pharma collaborators. 3. Urine tests are clinically different from blood tests - they are used for a subset of indications and are interpreted differently. Our device can also be adapted to test urine and saliva samples in the future.","author_name":"Eshwar Inapuri","votes":0,"created_at":"2021-03-09T02:13:04Z"}]},{"id":131733,"entity_id":"wefunder:comment:131733","question":"I noticed that you are using a different platform for this round.I previously invested with Republic.","author_name":"Steven Talcovitz","votes":3,"created_at":"2021-02-20T20:54:35Z","canonical_url":"https://wefunder.com/innamed#question-131733","answers":[{"id":131873,"entity_id":"wefunder:comment:131873","answer":"Yes! Wefunder now offers a great deal for YC companies, so we decided to work with them for this raise.","author_name":"Eshwar Inapuri","votes":5,"created_at":"2021-02-22T00:47:17Z"}]},{"id":229053,"entity_id":"wefunder:comment:229053","question":"I hope it does not end up like another Theranos!","author_name":"M Rezaul Karim","votes":2,"created_at":"2022-12-20T03:21:30Z","canonical_url":"https://wefunder.com/innamed#question-229053","answers":[]},{"id":226691,"entity_id":"wefunder:comment:226691","question":"Although my investment is small in this company, I have not heard anything about what’s going on, nor am I able to find out anything about my investment only that money came out of my account then… no visible signs of my investment. What am I missing. ThankU","author_name":"Sue Croft","votes":2,"created_at":"2022-11-24T13:30:39Z","canonical_url":"https://wefunder.com/innamed#question-226691","answers":[]},{"id":218903,"entity_id":"wefunder:comment:218903","question":"Can we get an update? Thanks in advance!","author_name":"Paul J Chambers","votes":2,"created_at":"2022-09-16T18:52:53Z","canonical_url":"https://wefunder.com/innamed#question-218903","answers":[]},{"id":218396,"entity_id":"wefunder:comment:218396","question":"Hi Eshwar. I would love to hear an update. I had sent an email a couple of weeks ago with no response. I hope the silence means there is a lot of progress!","author_name":"James Funaro","votes":2,"created_at":"2022-09-11T14:19:47Z","canonical_url":"https://wefunder.com/innamed#question-218396","answers":[]},{"id":218079,"entity_id":"wefunder:comment:218079","question":"Hi Eshwar, It has been a bit silent lately. [I have sent a similar message almost a year ago, Oct 2021]. When can we - your (new) investors - expect an update on performance, pipeline, financials, burn rate etc. Thank you","author_name":"Ronald Bazuin","votes":2,"created_at":"2022-09-08T10:12:18Z","canonical_url":"https://wefunder.com/innamed#question-218079","answers":[]},{"id":139165,"entity_id":"wefunder:comment:139165","question":"Greetings and congratulations on the progress! 1) Is cybersecurity part of the assessment criteria for FDA approval of the biomedical device? 2) What actions are being taken to address cyber risk and ensure patient health data is secure in the technology stack (e.g., IoT pen test, threat models, VDP, etc.)? Thanks and best of luck!","author_name":"Jesus Adrian Garcia Gonzalez","votes":2,"created_at":"2021-03-31T23:52:11Z","canonical_url":"https://wefunder.com/innamed#question-139165","answers":[{"id":139369,"entity_id":"wefunder:comment:139369","answer":"Yes, cybersecurity, data privacy and HIPAA compliance are definitely major considerations in our development of the software technology stack. We will be developing privacy policies, standard operating procedures, encryption protocols and having code reviews with 3rd parties to ensure we meet all requirements for secure and private health data transmission. FDA will not assess our software stack in it's totality, but they are sensitive to cybersecurity and data privacy and will be certain to review features as they pertain to blood testing and blood test data.","author_name":"Eshwar Inapuri","votes":2,"created_at":"2021-04-01T19:09:18Z"}]},{"id":133811,"entity_id":"wefunder:comment:133811","question":"Nice concept. 1) What are the different parameters like wbc, rbc , platelet count etc measured? 2) What is the accuracy of the tests? 3) For clinical trials, patients need to go to the centers for health check-up and appropriate dosage anyways. So, how/where does this solution benefit?","author_name":"Nikk P","votes":2,"created_at":"2021-03-06T14:37:58Z","canonical_url":"https://wefunder.com/innamed#question-133811","answers":[{"id":133854,"entity_id":"wefunder:comment:133854","answer":"Our technology can measure proteins, small molecules and clinical chemistries. Our first product will measure renal and metabolic markers with clinical grade accuracy. Many clinical trials are becoming virtual (https://www.nytimes.com/2021/02/18/health/clinical-trials-pandemic.html) where health check-ups and dosing is all managed digitally. We tie into this trend and offer an enhanced solution to perform virtual clinical trials.","author_name":"Eshwar Inapuri","votes":0,"created_at":"2021-03-06T23:23:46Z"}]},{"id":133662,"entity_id":"wefunder:comment:133662","question":"Hi. 1) Why aren't you executing a proper venture round instead of crowdfunding? 2) Who do you see as your primary competitors? Who else is trying to solve the problem that Innamed is seeking to solve?","author_name":"Howard M Hadley","votes":2,"created_at":"2021-03-05T18:03:36Z","canonical_url":"https://wefunder.com/innamed#question-133662","answers":[{"id":133687,"entity_id":"wefunder:comment:133687","answer":"1) We will be later this year! 2) Athelas and Scanwell are players in the home testing space that offer solutions for clinical trials. They're focused on cell counts and urinalysis, respectively (not blood testing for proteins and chemistries). Our technology is differentiated and patent protected.","author_name":"Eshwar Inapuri","votes":1,"created_at":"2021-03-05T21:19:05Z"}]},{"id":133595,"entity_id":"wefunder:comment:133595","question":"What is your targeted cost/pricing model for the end consumer or how much will the health insurance provider be charged if they offer full coverage to the consumer? Thanks! I definitely hope that this is where things will go in the future, I don't want to have to go to have blood work done if I can do it at home instead. :)","author_name":"Lester Erwin","votes":2,"created_at":"2021-03-05T04:48:00Z","canonical_url":"https://wefunder.com/innamed#question-133595","answers":[{"id":133659,"entity_id":"wefunder:comment:133659","answer":"We don't plan on charging the end consumer. Pharmaceutical companies or their contract research organizations will be paying for the product in the clinical trial market. We are aiming to use a subscription license model (similar to how someone pays for a Microsoft Office license on a monthly subscription basis). Pricing will be dependent on the exact solution being implemented for the customer (tests, software features, number of patients, etc.)","author_name":"Eshwar Inapuri","votes":1,"created_at":"2021-03-05T17:45:26Z"}]},{"id":131892,"entity_id":"wefunder:comment:131892","question":"(1) What specific metabolic markers will the HomeLab RMX cartridge be able to test for? (2) Can you provide a specific example of how in-home frequent blood monitoring can result in better, cheaper outcomes for patients? The reason I ask this is, in my mind, in order for this to achieve widespread adoption, attaining insurance coverage becomes essential. Insurance will cover this if the cost of frequent, in home testing is shown to be cheaper (better patient adherence) than the cost of the alternative (in doctor’s office testing) (3) What exactly is the nature of your collaboration with Jannsen? (4) Are you aware of any competitors working to create a similar product?","author_name":"Nathan B","votes":2,"created_at":"2021-02-22T06:37:36Z","canonical_url":"https://wefunder.com/innamed#question-131892","answers":[{"id":131944,"entity_id":"wefunder:comment:131944","answer":"Hi Nathan - thanks for the questions. Here are my answers: (1) The HomeLab RMX cartridge will include a subset of tests from the Comprehensive Metabolic Panel. (2) For example, patients taking mineralocorticoid receptor antagonists (MRAs) can use HomeLab to ensure electrolytes do not exceed safe levels which can cause adverse events (e.g. heart attacks). MRAs are known to reduce hospitalizations and mortality in certain patient populations so HomeLab would be ensuring safer use of the these types of therapies for improved patient outcomes. (3) We cannot share specifics on the collaboration at this time beyond what is on the page. (4) Though not direct competitors, other companies with at-home monitoring devices include Athelas (at-home blood cell counts) and Lucira Health (at-home Covid testing).","author_name":"Anup Singh","votes":2,"created_at":"2021-02-22T19:46:28Z"}]},{"id":131792,"entity_id":"wefunder:comment:131792","question":"I invested in Republic and i am very happy to see impressive revenue growth. I have few questions. 1. Do you expect to have similar revenue growth of 600% yoy for the next few years? why or why not? 2. What is the revenue projection and goal for the next five years(maybe revenue goal for 2025)? 3. What are your current revenue source? 4.How many HomeLab® system has been sold and how many blood test has been done at home using this HomeLab Thank you.","author_name":"Van Lal REM","votes":2,"created_at":"2021-02-21T12:16:05Z","canonical_url":"https://wefunder.com/innamed#question-131792","answers":[{"id":131874,"entity_id":"wefunder:comment:131874","answer":"We are aiming to continue revenue growth in 2021, but our next major revenue inflection point will be upon FDA clearance of the HomeLab system. Our current revenue is from pharmaceutical R\u0026amp;D collaborations. We are currently in the design for manufacturing (DFM) phase of the HomeLab system. This raise will provide the capital necessary for getting manufactured units in the hands of patients for evaluation this summer.","author_name":"Eshwar Inapuri","votes":2,"created_at":"2021-02-22T00:53:08Z"}]},{"id":277790,"entity_id":"wefunder:comment:277790","question":"How do we report the Capital Loss?","author_name":"Craig Ephraim","votes":1,"created_at":"2024-03-02T14:49:34Z","canonical_url":"https://wefunder.com/innamed#question-277790","answers":[]},{"id":263140,"entity_id":"wefunder:comment:263140","question":"What is the status of the company?","author_name":"Dwayne Ashley","votes":1,"created_at":"2023-09-23T12:12:42Z","canonical_url":"https://wefunder.com/innamed#question-263140","answers":[]},{"id":261352,"entity_id":"wefunder:comment:261352","question":"Hi Team. I have not got any update this year so far. Any updates? @Eshwar?","author_name":"Joyko AMOUZOU","votes":1,"created_at":"2023-09-07T00:29:57Z","canonical_url":"https://wefunder.com/innamed#question-261352","answers":[]},{"id":243642,"entity_id":"wefunder:comment:243642","question":"Hi Ishwar, I just learned that InnaMed was acquired by Fluxergy, but I never received an update from you. I see that the website has disappeared and there are no updates from the company. I invested in InnaMed because of its revolutionary technology. I don't see any communication from you past May 27, 2021. Now that the company is bought out, what happens to us investors? It is disturbing that the company was acquired, but we were not notified. I'd appreciate an email update from you to all investors. Thanks!","author_name":"Jilani Warsi","votes":1,"created_at":"2023-04-19T14:48:24Z","canonical_url":"https://wefunder.com/innamed#question-243642","answers":[]},{"id":237351,"entity_id":"wefunder:comment:237351","question":"Will shareholders get anything back? https://www.360dx.com/point-care-testing/fluxergy-acquires-innameds-blood-testing-tech-support-metabolic-panel#.ZAOUonbMI2w","author_name":"James Funaro","votes":1,"created_at":"2023-03-04T18:58:50Z","canonical_url":"https://wefunder.com/innamed#question-237351","answers":[]},{"id":235757,"entity_id":"wefunder:comment:235757","question":"I see that the Innamed’s website now shows “page not found” so I can assume that the business has completely closed down. However, I think a lot of investors here should be interested to know why the CEO Eshwar was the Head of Product at Ventrice Health since Sep 2021 before all these announcements were made to the investors? And surprisingly Ventrice Health is founded by Dan Bensimhon the lead investor in Innamed. Any explanations?","author_name":"J T","votes":1,"created_at":"2023-02-21T18:58:22Z","canonical_url":"https://wefunder.com/innamed#question-235757","answers":[]},{"id":216041,"entity_id":"wefunder:comment:216041","question":"Is there any update? don't see any updates in any of your social accounts. Is the company still in business?","author_name":"J T","votes":1,"created_at":"2022-08-21T02:33:41Z","canonical_url":"https://wefunder.com/innamed#question-216041","answers":[]},{"id":212545,"entity_id":"wefunder:comment:212545","question":"is thre any update for 2022?","author_name":"Andrea Dalle Molle","votes":1,"created_at":"2022-07-24T18:39:13Z","canonical_url":"https://wefunder.com/innamed#question-212545","answers":[]}],"faq":[{"question":"I noticed that you are using a different platform for this round.I previously invested with Republic.","answer":"Yes! Wefunder now offers a great deal for YC companies, so we decided to work with them for this raise."},{"question":"I invested in Republic and i am very happy to see impressive revenue growth. I have few questions. 1. Do you expect to have similar revenue growth of 600% yoy for the next few years? why or why not? 2. What is the revenue projection and goal for the next five years(maybe reven...","answer":"We are aiming to continue revenue growth in 2021, but our next major revenue inflection point will be upon FDA clearance of the HomeLab system. Our current revenue is from pharmaceutical R\u0026amp;D collaborations. We are currently in the design for manufacturing (DFM) phase of the HomeLab system. This raise will provide the capital necessary for getting manufactured units in the hands of patients for evaluation this summer."},{"question":"(1) What specific metabolic markers will the HomeLab RMX cartridge be able to test for? (2) Can you provide a specific example of how in-home frequent blood monitoring can result in better, cheaper outcomes for patients? The reason I ask this is, in my mind, in order for this ...","answer":"Hi Nathan - thanks for the questions. Here are my answers: (1) The HomeLab RMX cartridge will include a subset of tests from the Comprehensive Metabolic Panel. (2) For example, patients taking mineralocorticoid receptor antagonists (MRAs) can use HomeLab to ensure electrolytes do not exceed safe levels which can cause adverse events (e.g. heart attacks). MRAs are known to reduce hospitalizations and mortality in certain patient populations so HomeLab would be ensuring safer use of the these t..."},{"question":"Hello, congratulations on your success so far. Can you provide a time-frame (approximately) when you are planning to convert to equity this SAFE and the convertible from the Republic round? What exit strategy you are vision? From a short research made to the non direct competi...","answer":"Hi Anna - happy to provide clarity. The SAFE from this round will be converted to equity upon a subsequent priced round financing. We are aiming to raise an institutional (VC-led) Series A later this year. When we do so, this event would trigger conversion of your SAFE to equity. As you stated, we will need additional capital to commercialize and an institutional Series A will provide that capital. From there, we can focus on growth (Series B followed by IPO) or exit (acquisition) opportuniti..."},{"question":"Hi Eshwar and Anup, how much money are you guys looking to raise this round?","answer":"Hey Libin! We're looking to raise $1M on Wefunder. We'll be assessing all opportunities and making a decision from there."}]}}}